The cord blood industry came into existence in the early 1990’s with the formation of several cord blood banks in the U.S. and worldwide. It has also been almost 40 years since it was first proposed that stem and progenitor cells were present in human cord blood. [Read more…]
Because cord blood present within a newborn’s umbilical is rich with stem cells, it can be collected and stored for future medical use.
The global cord blood banking industry has been rapidly maturing in recent years. In part, this has been caused by changes in processing, storage, and transplantation technologies. These changes require executives and industry decision-makers to have a firm understanding of emerging trends.
One of the most notable cord blood industry trends has been a diversification of services. Put simply, cord blood banks are becoming diversified stem cell biobanks. [Read more…]
HOUSTON, July 6, 2020 — Physician-investigators at Johns Hopkins University Hospital report on the promising data of treatment of COVID-19 induced acute respiratory distress syndrome with allogeneic, cord blood derived T-regulatory (Treg) cell therapy (manufactured by Cellenkos®), published in peer reviewed journal of Annals of Internal Medicine. Both patients were critically ill and intubated (one on ECMO). Both had failed Tociluzimab (Actemra, Roche) and had multiorgan failure. Patients received cell therapy under FDA Emergency Use IND for up to 3 doses. [Read more…]
CRISPR Therapeutics and Vertex Pharmaceuticals Have Been Awarded an FDA RMAT Designation for CTX001™ in the Treatment of Severe Hemoglobinopathies
CTX001 has received Orphan Drug Designation from the U.S. FDA for transfusion-dependent beta thalassemia and from the European Medicines Agency (EMA) for sickle cell disease and transfusion-dependent beta thalassemia
ZUG, Switzerland and Cambridge, MA, May 11, 2020 — CRISPR Therapeutics (Nasdaq: CRSP) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. FDA RMAT designation to CTX001, an investigational, autologous, gene-edited hematopoietic stem cell therapy, for the treatment of severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). [Read more…]
Where do stem cells come from? Learn the basics of these “master cells” to better understand their therapeutic potential.
With large-scale trials underway using stem cell therapeutics to address the complications of COVID-19, these cells are receiving greater clinical attention than ever before in history. Currently, the Australian stem cell company (Mesoblast) is enrolling for a 300 person trial against COVID-19 complications and the American company (Athersys) is enrolling for a 400 person trial.
If succesful, these trials could forever alter the course of the current pandemic—as well as the future of stem cell therapeutics themselves.
In this article:
- An Introduction to Human Stem Cells
- Types of Stem Cells
- Where Do Stem Cells Come From?
- The Donation Process
- What Can Stem Cells Treat?
- Stem Cells for Testing New Drugs
- The Benefits of Stem Cell Transplant
- The Survival Rate of Stem Cell Therapy